Related Experiment Video
Updated: Jun 25, 2026

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
Published on: November 2, 2018
Loss of IKKbeta activity increases p53 stability and p21 expression leading to cell cycle arrest and apoptosis
Pei-Ming Yang1, Wei-Chien Huang, Yi-Chu Lin
1Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Abstract:
Elevated levels of NF-kappaB are frequently detected in many inflammatory diseases and cancers. Blocking the IKK-NF-kappaB pathway has been seen as a promising approach for new therapies. By employing the dominant-negative mutant of IKKbeta, our data revealed that loss of IKKbeta activity reduces not only the proliferation and invasion of lung adenocarcinoma A549 cells in vitro but also the tumour formation, metastasis and angiogenesis in mouse xenograft model. Treatment of IKKbeta inhibitors (CYL-19s and CYL-26z) leads to the arrest of cell cycle progression at G1 and G2/M, followed by apoptosis. IKKbeta inhibitors can increase the protein stability, nuclear accumulation and promoter-binding activity of p53, leading to the p21 gene transcription. Furthermore, knockdown of IKKbeta by siRNA increased the stability and expression of p53 and p21 promoter activity. In addition, IKKbeta inhibitor-induced p53 and p21 expressions were augmented in the presence of IKKbeta siRNA. Correlation between p53 acetylation and its protein stabilization was also seen after treatment with IKKbeta inhibitors. These results suggest that loss of IKKbeta activation is important for the enhancement of p53 stability, leading to p21 expression and cell cycle arrest and apoptosis of tumour cells.
Insights
Blocking the IKK-NF-kappaB pathway inhibits lung cancer cell growth and metastasis. This approach enhances p53 stability, promoting cell cycle arrest and apoptosis in tumor cells.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Elevated nuclear factor-kappa B (NF-kappaB) signaling is implicated in various inflammatory diseases and cancers.
- Targeting the inhibitor of kappa B kinase (IKK)-NF-kappaB pathway presents a potential therapeutic strategy.
Purpose of the Study:
- To investigate the role of IKKbeta in lung adenocarcinoma progression.
- To evaluate the therapeutic potential of inhibiting IKKbeta activity.
Main Methods:
- Utilized a dominant-negative mutant of IKKbeta and IKKbeta inhibitors (CYL-19s, CYL-26z).
- Assessed effects on A549 lung adenocarcinoma cells in vitro and in a mouse xenograft model.
- Examined cell cycle progression, apoptosis, p53 stability, nuclear accumulation, promoter-binding activity, and p21 gene transcription.
- Employed small interfering RNA (siRNA) for IKKbeta knockdown.
Main Results:
- Loss of IKKbeta activity reduced proliferation, invasion, tumor formation, metastasis, and angiogenesis.
- IKKbeta inhibition induced G1 and G2/M cell cycle arrest and apoptosis.
- Inhibitors increased p53 protein stability, nuclear accumulation, and promoter-binding activity, enhancing p21 transcription.
- IKKbeta knockdown potentiated these effects and correlated with p53 acetylation.
Conclusions:
- IKKbeta inhibition is crucial for enhancing p53 stability and subsequent p21 expression.
- This mechanism leads to cell cycle arrest and apoptosis in tumor cells, highlighting IKKbeta as a therapeutic target.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Inhibition of Cdk Activity
Negative Regulator Molecules
The Intrinsic Apoptotic Pathway
